Behzad Habibi Khameneh, MD
Neurology · Danbury, CTNPI 1669447538
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,791 and has fallen 91.6% since, to $150 in 2024.
Across 137 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$397
- Novartis$253
- Biogen$194
- Supernus Pharmaceuticals, Inc.$193
- Lilly USA, LLC$157
- Sanofi$142
- plus $1K from 28 others
Across 14 payments — averaging $5214.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$56K
- H. Lundbeck A S$16K
- Lundbeck LLC$1K
What the payments were for
- Food & beverage$2,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $397 |
| Novartis | 14 | $253 |
| Biogen | 11 | $194 |
| Supernus Pharmaceuticals, Inc. | 11 | $193 |
| Lilly USA, LLC | 5 | $157 |
| Sanofi | 8 | $142 |
| Argenx US, Inc. | 1 | $132 |
| Avanir Pharmaceuticals, Inc. | 9 | $124 |
| Acadia Pharmaceuticals Inc | 8 | $105 |
| Boston Scientific | 1 | $92 |
| Alnylam Pharmaceuticals Inc. | 3 | $76 |
| EMD Serono, Inc. | 5 | $74 |
| Sunovion Pharmaceuticals Inc. | 3 | $61 |
| GE HealthCare | 3 | $53 |
| Lundbeck LLC | 3 | $52 |
| Eisai Inc. | 2 | $50 |
| Amgen | 3 | $46 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| CSL Behring | 2 | $35 |
| Grifols USA, LLC | 2 | $34 |
| Bausch Health US, LLC | 1 | $30 |
| Promius Pharma LLC | 2 | $28 |
| Adlon Therapeutics L.p. | 2 | $28 |
| Greenwich Biosciences, Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| SK Life Science, Inc. | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Rhodes Pharmaceuticals L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$132
How this compares
$2,607 in reported general payments places this provider in the 60th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 40 | $44,759 |
| Lacosamide | 18 | $10,586 |
| Entacapone | 26 | $4,805 |
| Gabapentin | 152 | $2,791 |
| Donepezil Hcl | 152 | $2,185 |
| Levetiracetam | 44 | $1,733 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 44 | $1,055 |
| Memantine Hcl | 26 | $1,035 |
| Primidone | 44 | $1,033 |
| Nortriptyline Hcl | 55 | $874 |
| Topiramate | 26 | $682 |
| ClopidogrelClopidogrel Bisulfate | 30 | $491 |
| Lamotrigine | 20 | $414 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $324 |
| Escitalopram Oxalate | 16 | $323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $397 | $44,75940 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $18 | $27211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 280 neurology providers in Connecticut.
Other neurology in Danbury
- David GrecoDanbury$34K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.